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Atrial-ventricular differences in rabbit cardiac
voltage-gated Na1 currents: Basis for atrial-selective
block by ranolazineRachel E. Caves, PhD, Hongwei Cheng, PhD, Stéphanie C. Choisy, PhD,
Hanne C. Gadeberg, PhD, Simon M. Bryant, PhD, Jules C. Hancox, PhD, FRSB, FBPhS,
Andrew F. James, DPhil
From the School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol,
United Kingdom.BACKGROUND Class 1 antiarrhythmic drugs are highly effective in
restoring and maintaining sinus rhythm in atrial ﬁbrillation patients
but carry a risk of ventricular tachyarrhythmia. The antianginal
agent ranolazine is a prototypic atrial-selective voltage-gated
Na1 channel blocker but the mechanisms underlying its atrial-
selective action remain unclear.
OBJECTIVE The present study examined the mechanisms underly-
ing the atrial-selective action of ranolazine.
METHODS Whole-cell voltage-gated Na1 currents (INa) were re-
corded at room temperature (w22C) from rabbit isolated left atrial
and right ventricular myocytes.
RESULTS INa conductance density wasw1.8-fold greater in atrial
than in ventricular cells. Atrial INa was activated at command poten-
tialsw7 mV more negative and inactivated at conditioning poten-
tials w11 mV more negative than ventricular INa. The onset of
inactivation of INa was faster in atrial cells than in ventricular my-
ocytes. Ranolazine (30 mM) inhibited INa in atrial and ventricular
myocytes in a use-dependent manner consistent with preferentialThe study was supported by project grants from the British Heart Foun-
dation (BHF PG/14/21/30673, PG/14/42/30886 and PG/15/55/31568).
Address reprint requests and correspondence: Dr Andrew F. James,
School of Physiology, Pharmacology & Neuroscience, Faculty of Biomed-
ical Sciences, University of Bristol, University Walk, Bristol, BS8 1TD,
United Kingdom. E-mail address: a.james@bristol.ac.uk.
1547-5271/© 2017 The Authors. Published by Elsevier Inc. on behalf of Heart Rhyth
is an open access article under the CC BY license (http://creativecommons.org/licenactivated/inactivated state block. Ranolazine caused a signiﬁcantly
greater negative shift in voltage of half-maximal inactivation in
atrial cells than in ventricular cells, the recovery from inactivation
of INa was slowed by ranolazine to a greater extent in atrial myocytes
than in ventricular cells, and ranolazine produced an instantaneous
block that showed marked voltage dependence in atrial cells.
CONCLUSION Differences exist between rabbit atrial and ventricu-
lar myocytes in the biophysical properties of INa. The more negative
voltage dependence of INa activation and inactivation, together
with trapping of the drug in the inactivated channel, underlies an
atrial-selective action of ranolazine.
KEYWORDS Antiarrhythmic drug; Atrial myocytes; Cardiac regional
heterogeneity; Na1 channel blocker; Ventricular myocytes
(Heart Rhythm 2017;14:1657–1664) © 2017 The Authors. Pub-
lished by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Atrial ﬁbrillation (AF), characterized by rapid and irregular
electrical activation of the atria, reduced cardiac output,
poor response to exercise, and fatigue, is the most commonly
occurring clinical arrhythmia.1 AF is associated with signiﬁ-
cant morbidity and mortality, principally through an elevated
risk of thromboembolism and ischemic stroke owing to inad-
equate emptying of the atria, although the elevated ventricu-
lar rate can also contribute to tachycardia-induced
cardiomyopathy and decompensated heart failure.1 The con-
dition tends to be progressive, with paroxysms of AF leadingwith time to persistent and permanent AF.1 The progressive
nature of AF is thought to arise through the elevated rate
causing electrical and structural remodeling that stabilizes
the arrhythmia.1 Early intervention to prevent and/or control
the arrhythmia is therefore highly desirable.1,2
The activation of voltage-gated Na1 channels underlies
the propagation and conduction of the action potential
through the heart, whereas their subsequent inactivation ini-
tiates a refractory period that is usually determined by the
duration of the action potential.3 Voltage-gated Na1 channels
are a major target for antiarrhythmic drugs, as the combined
effects of reduction in membrane excitability, conduction ve-
locity slowing, and prolongation of the refractory period can
both suppress triggered activity and extinguish reentrant
activity.2 Blockers of voltage-gated Na1 channels with rela-
tively slow dissociation kinetics (ie, the class Ia and Ic anti-
arrhythmic drugs of the Vaughan-Williams classiﬁcation)
are effective in the cardioversion of early-onset AF and them Society. This
ses/by/4.0/).
http://dx.doi.org/10.1016/j.hrthm.2017.06.012
1658 Heart Rhythm, Vol 14, No 11, November 2017maintenance of sinus rhythm.4,5 The class Ic drugs, ﬂecainide
and propafenone, are recommended as a suitable “pill-in-the-
pocket.”5,6
Despite the effectiveness of class Ic antiarrhythmic drugs
in the treatment of AF, the Cardiac Arrhythmia Suppression
Trial demonstrated that these drugs carried an increased mor-
tality in patients with structural abnormalities, precluding
their use in such patients.7 Consequently, there has been
considerable interest in alternative agents that allow atrial-
selective targeting of voltage-gated Na1 channels.2,8,9 In
principle, atrial selectivity of action might arise through (1)
atrial-ventricular differences in the molecular, biophysical,
or pharmacologic properties of voltage-gated Na1 channels
and/or (2) atrial-ventricular differences in the resting mem-
brane potential and in conﬁguration of the action potential.
Evidence from canine, guinea pig, rabbit, and rat cardiac my-
ocytes supports the existence of atrial-ventricular differences
in Na1 channel function: compared with the voltage-gated
Na1 channel current (INa) of ventricular myocytes, atrial
INa inactivates at more negative voltages, with more rapid
onset, and recovers more slowly from inactivation.10–13
The antianginal drug ranolazine (Ranexa) is a prototypic
example of a drug with a putative atrial-selective action
against voltage-gated Na1 channels.8,11 Ranolazine has
been found to suppress the incidence of AF in anginal
patients and is suggested to be effective in pharmacologic
cardioversion of patients with early-onset AF.14–16
Ranolazine shows structural homology to lidocaine and has
been suggested to bind to the local anesthetic binding site
within the central cavity of the pore.17,18 However, the
mechanism for the atrial-selective action of the drug remains
unclear. Preferential binding of ranolazine to the inactivated
state of the channel and slowing of recovery from inactiva-
tion have been suggested to underlie use-dependent block,
so that atrial selectivity arises from the inactivation of INa
at more negative voltages in atrial cells.19,20 On the other
hand, ranolazine has been suggested to be an open channel
blocker that becomes trapped in the inactivated state.21,22
The objective of this study was to investigate atrial-
ventricular differences in the properties of INa and its block
by ranolazine in rabbit cardiac myocytes.
Methods
Detailed methods are available in Supplemental Information
online.
Rabbit cardiac myocyte isolation
Rabbit right ventricular and left atrial myocytes were isolated
as described previously, using procedures approved by the
University of Bristol Animal Welfare and Ethics Board in
accordance with UK legislation and the Guide for the Care
and Use of Laboratory Animals.23,24
Whole-cell recording of voltage-gated Na1 currents
Whole-cell Na1 currents (INa) were recorded at room temper-
ature using the patch-clamp technique and symmetrical inter-
nal and external [Na1] (10 mM).Ranolazine
Ranolazine (Sequoia Research Products Ltd, Pangbourne,
UK) was used at 30 mM to produce signiﬁcant use-
dependent block of the fast component of INa.
22Statistics
Data are presented as the mean6 standard error of the mean.
P, .05 was used as the limit of statistical conﬁdence. Curve
ﬁtting was performed by nonlinear least squares using Igor
Pro v6 (WaveMetrics Inc, Portland, OR).Results
Depolarizing pulses activated inward currents with rapid ki-
netics of activation and inactivation typical of INa in both
atrial and ventricular myocytes (Figure 1A and B). The cur-
rents of both cell types showed a U-shaped current density–
voltage relation with a zero-current potential close to zero
mV, consistent with their Na1 selectivity (Figure 1C). How-
ever, INa from atrial myocytes activated at more negative
voltages than ventricular INa, with measurable inward cur-
rents being evident from voltages of 260 mV and positive
and reaching a maximum at approximately240 mV in atrial
cells, whereas INa in ventricular myocytes were activated
from 250 mV and reached a maximum at w230 mV
(Figure 1C). The current density–voltage relations of each
cell type were ﬁtted by a modiﬁed Boltzmann relation
(Supplemental Equation 1) and the more negative voltage
dependence of activation of atrial INa was reﬂected in a
mean half-maximal voltage of activation (Vhalf,act) approxi-
mately 7 mV more negative than that of ventricular INa (P
, .0001; Supplemental Table 1). Although there was no dif-
ference in the slope factors, atrial myocytes showed a
maximal conductance density almost twice that of ventricular
cells (P , .0001; Supplemental Table 1). Atrial INa also
showed shorter times to peak current than ventricular cur-
rents, suggesting more rapid activation of atrial voltage-
gated Na1 channels (Figure 1D).
Both atrial and ventricular INa showed voltage-dependent
inactivation in response to 1.5-second conditioning pulses
from 2150 mV to 250 mV (Figure 2). Currents were
maximal from conditioning potentials of 2130 mV and
negative but showed voltage-dependent inactivation at
more positive potentials. The rate of onset of INa inactivation
was examined by ﬁtting a single decaying exponential rela-
tion (Supplemental Equation 2) to the currents activated
from a conditioning potential of 2150 mV (see inserts to
Figure 2A and B). Inactivation of INa was faster in atrial cells
than in ventricular myocytes (t: atrial, 0.64 6 0.02 ms, n 5
29; ventricular, 1.116 0.03 ms, n5 29; P, .0001, unpaired
Student t test). Atrial INa also inactivated at more negative
voltages than the current in ventricular cells, with signiﬁcant
differences evident between the 2 cell types in the range from
2110 mV to280 mV (Figure 2C). The voltage dependence
of inactivation was ﬁtted by a Boltzmann relation
(Supplemental Equation 3) and the mean voltage of half-
maximal inactivation (Vhalf,inact) of atrial cells wasw11.5 mV
Figure 1 Atrial-ventricular differences in fast-Na1 current (INa) density–voltage relations.A:Representative current traces recorded from an atrial myocyte on
depolarization to a range of voltages. Arrow indicates zero current level. Insert shows voltage pulse protocol. B: Representative current traces recorded from a
ventricular myocyte on depolarization to a range of voltages. Arrow indicates zero current level. Voltage pulse protocol as for A. C: Mean INa density–voltage
relations for atrial (ﬁlled circles, n5 17) and ventricular (open circles, n5 17) myocytes. Solid lines represent ﬁts to Supplemental Equation 1. Data were signif-
icantly different by both cell type (P, .0001) and voltage (P, .0001), with signiﬁcant interaction (P, .0001; 2-way repeatedmeasures analysis of variance [RM
ANOVA]). *P, .05; ****P, .0001 vs ventricular; Bonferroni post hoc test. Inset shows the corresponding mean INa density–voltage relations without normal-
ization to whole-cell capacitance. Data were signiﬁcantly different by both cell type (P5 .0002) and voltage (P, .0001), with signiﬁcant interaction (P, .0001;
2-way RM ANOVA). **P , .01; ****P , .0001 vs ventricular; Bonferroni post hoc test. D: Voltage dependence of time-to-peak INa (TTP) for atrial (ﬁlled
circles, n 5 17) and ventricular (open circles, n 5 17) myocytes. Data were signiﬁcantly different by both cell type (P , .0001) and voltage (P , .0001),
with signiﬁcant interaction (P5 .0355; 2-way RM ANOVA). *P, .05; ****P, .0001 vs ventricular; Bonferroni post hoc test. The membrane time constants
were 0.168 6 0.009 ms for atrial myocytes (n 5 17) and 0.327 6 0.026 ms for ventricular cells (n 5 17; P , .0001, unpaired Student t test).
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(Supplemental Table 1).
The use-dependent interaction of ranolazine (RAN, 30
mM) with voltage-gated Na1 channels in rabbit atrial and
ventricular myocytes was investigated by examining the ef-
fects of shortening of diastolic interval (DI) and of changing
the holding potential (HP) on the degree of block during ﬁxed
trains of 40 consecutive pulses of 20 ms duration to230 mV
(Figure 3). The effects of DI of 110 ms, 60 ms, and 40 ms
were examined in each cell at each HP. If the drug interaction
with the resting channel is weak, then RANwill tend to disso-
ciate during the DI at an HP of 2120 mV. Reduction of DI
can be expected to lead to accumulation of block as the
time for unbinding becomes abbreviated. The effect of
voltage on block was examined by performing experiments
at HPs of 2120 mV, 2110 mV, and 2100 mV in different
cells (respectively, panels i, ii, and iii in Figure 3A and B).
Depolarization of the HP can be expected to increase accu-
mulation of block, as recovery from inactivation to the rested
state will be limited. As reported for currents through recom-
binant voltage-gated Na1 channel subunits and endogenous
channels in canine cardiac myocytes,20–22,25–27 30 mM
RAN inhibited INa in a use-dependent manner, the level of
block accumulating over the 40 consecutive pulses, the block
being greater at shorter DI (Figure 3A and B). A degree ofinstantaneous block (10%–40%) was evident at the ﬁrst pulse
and the degree of block increased over subsequent pulses,
reaching between 25% and 70% total block at the 40th pulse.
The total level of block achieved on the 40th pulse depended
on DI (P , .001, factorial mixed analysis of variance [AN-
OVA]) and HP (P , .001; Figure 3C). The inhibition of
INa by RAN was different between atrial and ventricular my-
ocytes (P , .001) and there was an interaction between cell
type and HP (P5 .02). This is clear from panels i, ii, and iii of
Figure 3C: in both atrial and ventricular cells, mean total
block increased with shortening DI at each HP. However,
whereas in ventricular cells total block at each DI increased
with less negative HP over the range from 2120 mV to
2100 mV, in atrial cells the voltage dependence of block
was apparent primarily between 2120 mV and 2110 mV.
In consequence, the differences between atrial and ventricu-
lar cells in total block by RAN were most marked at an HP of
2110 mV (Figure 3C). In summary, the data suggest a differ-
ence between atrial and ventricular myocytes in the voltage
dependence of block by RAN.
Use-dependent block by RAN, quantiﬁed as the difference
in percentage block between the ﬁrst and the 40th pulse, was
also different between atrial and ventricular cells (factorial
mixed ANOVA, P 5 .001; Figure 4). The percentage use-
dependent block ranged fromw15% tow40%. Disregarding
Figure 2 Atrial-ventricular differences in steady-state voltage-dependent
inactivation of INa. A: Representative current traces recorded from an atrial
myocyte on depolarization to 230 mV after conditioning at a range of volt-
ages. Arrow indicates zero current level. Inserts show voltage pulse protocol
and current trace elicited from a conditioning potential of 2150 mV on an
expanded time scale. Dashed line represents ﬁts to Supplemental Equation
2. B: Representative current traces recorded from a ventricular myocyte on
depolarization to 230 mV after conditioning at a range of voltages. Arrow
indicates zero current level. Voltage pulse protocol as in A. Insert shows cur-
rent trace elicited from a conditioning potential of2150 mV on an expanded
time scale. Dashed line represents ﬁts to Supplemental Equation 2. C:Mean
INa steady-state voltage-dependent inactivation curves for atrial (ﬁlled cir-
cles, n 5 29) and ventricular (open circles, n 5 29) myocytes. INa were
normalized to the amplitude from a conditioning potential of 2150 mV.
Dashed lines represent ﬁts to Supplemental Equation 3. Data were signiﬁ-
cantly different by both cell type (P , .0001) and voltage (P , .0001),
with signiﬁcant interaction (P , .0001; 2-way repeated measures analysis
of variance). ****P , .0001 vs ventricular; Bonferroni post hoc test.
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shorter DI (P, .001), consistent with preferential association
of the drug with activated states of the channel. Similarly, dis-
regarding cell type and DI, use-dependent block was different
by HP (P , .001). However, though the increase in use-
dependent block at shorter DI was similar between atrial
and ventricular cells, the effect of HP differed between the
2 cell types: whereas, over the 3 DI, use-dependent block
increased at more depolarized HPs in ventricular cells, use-
dependent block was reduced by depolarization of the HP
in atrial cells; this was particularly evident at the shorter DI.
The difference between atrial and ventricular cells in thevoltage dependence of use-dependent block is reﬂected in
the signiﬁcant interaction between cell type and HP for these
data (P , .001; Figure 4). As a result, the use-dependent
block at each DI was smaller in atrial cells than in ventricular
myocytes at2100 mV (Figure 4C). There were also marked
differences between the 2 cell types in the instantaneous
block (P , .0001, 2-way ANOVA; Figure 5). Whereas in
atrial cells instantaneous block was markedly increased by
depolarization of the HP, there was no obvious voltage
dependence to instantaneous block in ventricular cells. In
consequence, instantaneous block was signiﬁcantly greater
in atrial cells compared with ventricular cells at 2110 mV
and 2100 mV (Figure 5).
The effect of RAN on steady-state inactivation was exam-
ined in atrial and ventricular myocytes. In both cell types,
treatment with RAN was associated with a negative shift in
Vhalf,inact (Figure 6). The shift was approximately 1.8-fold
greater in atrial myocytes than in ventricular myocytes (P
, .05). However, time-matched control experiments showed
a time-dependent shift in Vhalf,inact in atrial and ventricular
myocytes, with no signiﬁcant difference between the cell
types in the magnitude of the shift (Figure 6). Although the
RAN-induced shift in Vhalf,inact was signiﬁcantly greater
than the time-matched control in atrial myocytes (P , .01),
this was not the case in ventricular cells. Thus, RAN caused
a negative shift in Vhalf,inact that achieved the level of statisti-
cal conﬁdence in atrial myocytes. RAN also caused an
apparent acceleration in the time constant of inactivation
from a conditioning potential of 2150 mV in both atrial
(12.4% 6 2.23%, n 5 7, P 5 .0015, paired t test) and ven-
tricular (11.7%6 1.72%, n5 5, P5 .0024, paired t test) my-
ocytes. There was no difference between the 2 cell types in
the acceleration of inactivation (P 5 .8429, unpaired t test).
In both atrial and ventricular myocytes, INa recovered
from inactivation with a biexponential time course, with a
fast time constant (tf) of 10–20 ms and a slow time constant
(ts) of 120–300 ms (Figure 7A). The fast and slow compo-
nents contributed approximately equally to recovery in
both cell types, and although the mean fast and slow time
constants were larger (ie, slower) in atrial than in ventricular
cells, this did not achieve the level of statistical conﬁdence
(Figure 7B and C). The recovery from inactivation was
slowed by RAN in both cell types. However, RAN appeared
more effective in atrial cells, slowing mean tf by 2.4-fold (P
, .05) and ts by 1.8-fold (P , .001), whereas in ventricular
cells mean tf was slowed by 1.5-fold (not statistically signif-
icant) and ts by 1.6-fold (P, .05) (Figure 7B). The contribu-
tion of the slow component of recovery was increased by
RAN by 15%–20% in both cell types (Figure 7C).Discussion
Atrial-ventricular differences in INa
Clear atrial-ventricular differences were found in the bio-
physical properties of rabbit cardiac voltage-gated Na1 cur-
rents: atrial INa was activated at command potentials w7
mV more negative and inactivated at conditioning potentials
Figure 3 Use-dependent block of INa by ranolazine (RAN, 30 mM). A:Mean normalized current amplitudes recorded by a series of 40 pulses to 230 mV at
diastolic interval (DI) of 110 ms (circles), 60 ms (squares), and 40 ms (triangles) in atrial myocytes (ﬁlled symbols) from holding potentials (HPs) of (i)2120 mV
(n5 6), (ii)2110 mV (n5 6), and (iii)2100 mV (n5 5) in the presence of RAN. Currents were normalized to the currents elicited in the absence of RAN by the
corresponding pulse number.B:Mean normalized current amplitudes recorded using the same protocol as used in A from ventricular myocytes (open symbols) in
the presence of RAN fromHPs of (i)2120mV (n5 5), (ii)2110mV (n5 6), and (iii)2100mV (n5 9).C: Themean percentage total block elicited by the 40th
pulse at DIs of 110, 60, and 40 ms from atrial (ﬁlled columns) and ventricular (open columns) myocytes at HPs of (i)2120 mV, (ii)2110 mV, and (iii)2100 mV
(sample sizes correspond to A and B). Total block was signiﬁcantly different by factorial mixed analysis of variance (P, .001). Data were signiﬁcantly different
by DI (P, .001), HP (P, .001), and cell type (P, .001). There was a signiﬁcant interaction between cell type and HP (P5 .02). In Bonferroni post hoc tests, the
effect of 110 ms DI was signiﬁcantly different from 60 ms (P5 .014) and 40 ms (P, .001) but there was no statistical conﬁdence in the difference between DI of
60 ms and 40 ms (P5 .558). Similarly, the effect of an HP of2120 mVwas signiﬁcantly different from both2110 mV (P, .001) and2100 mV (P, .001) and
the effect of 2110 mV was signiﬁcantly different from 2100 mV (P 5 .046).
Figure 4 Effect of holding potential (HP) on percentage use-dependent block by ranolazine. A: Mean percentage use-dependent block at diastolic interval
(DI) of 110, 60, and 40 ms in atrial (ﬁlled columns, n5 6) and ventricular (open columns, n5 5) from an HP of2120 mV. B: Percentage use-dependent block at
DI of 110, 60, and 40 ms in atrial (ﬁlled columns, n5 6) and ventricular (open columns, n5 6) from an HP of2110 mV. C: Percentage use-dependent block at
DI of 110, 60, and 40 ms in atrial (ﬁlled columns, n5 5) and ventricular (open columns, n5 9) from an HP of2100 mV. Use-dependent block was signiﬁcantly
different by factorial mixed analysis of variance (P, .001). Data were signiﬁcantly different by DI (P, .001), HP (P, .001), and cell type (P5 .001). There
was a signiﬁcant interaction between cell type and HP (P , .001). In Bonferroni post hoc tests, the effect of 110 ms DI was signiﬁcantly different from 60 ms
(P5 .001) and 40 ms (P, .001) but there was no statistical conﬁdence in the difference between DI of 60 ms and 40 ms (P5 .146). Similarly, the effect of an
HP of2120 mV was signiﬁcantly different from both2110 mV (P, .001) and2100 mV (P, .001) but the effect of2110 mV was not different from2100
mV (P 5 1.000).
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Figure 5 Effect of holding potential (HP) on instantaneous block by rano-
lazine. Data show mean percentage block on the ﬁrst pulse to 230 mV at a
diastolic interval of 110ms fromHPs of2120,2110, and2100mV in atrial
(ﬁlled columns; respectively, 6, 6, and 5 cells) and ventricular (open columns;
respectively, 5, 6, and 9 cells) myocytes. **P, .01; ****P, .0001; 2-way
analysis of variance with Bonferroni post hoc test vs atrial cells at the corre-
sponding HP.
1662 Heart Rhythm, Vol 14, No 11, November 2017w11 mVmore negative than ventricular INa, and the onset of
activation and inactivation of INa were also faster in atrial
cells than in ventricular myocytes. In these respects, the dif-
ferences in INa between rabbit atrial and ventricular cells in
the present study were similar to those reported previously
in cardiac myocytes from various species.10–13 On the other
hand, in contrast to previous reports from rat and guinea
pig cardiac myocytes, there was no signiﬁcant difference
between rabbit atrial and ventricular cells in the rate of
recovery of INa from inactivation in the present study.
10,12
Signiﬁcant atrial-ventricular differences in block of INa by ra-
nolazine were also evident: (1) ranolazine caused a signiﬁ-
cantly greater negative shift in Vhalf,inact in atrial cells thanFigure 6 Effect of ranolazine (RAN) on half-maximal voltage of steady-
state inactivation. Data shown are the mean changes in Vhalf,inact caused by 30
mMRAN for atrial (ﬁlled column, n5 7) and ventricular (open column, n5
5) myocytes. Hatched columns show corresponding time-matched controls
in the absence of RAN for 6 atrial and 5 ventricular myocytes. *P , .05;
**P , .01; 2-way analysis of variance with Bonferroni post hoc test.in ventricular cells, as has been reported previously in canine
cardiac myocytes11; (2) the recovery from inactivation of INa
was slowed by ranolazine to a greater extent in atrial myo-
cytes than in ventricular cells; and (3) although there was lit-
tle effect of HP on instantaneous block in ventricular cells, in
atrial cells ranolazine produced an instantaneous block that
showed marked voltage dependence, increasing from
w16% block at an HP of 2120 mV to w36% at 2100
mV. The atrial-selective slowing of recovery from inactiva-
tion contrasts somewhat with a report showing little atrial-
ventricular difference in the recovery from block in canine
cardiac myocytes.22 Although voltage-dependent instanta-
neous block by ranolazine has been reported to be present
in canine atrial cells and absent in canine ventricular cells,
the degree of voltage dependence and the level of instanta-
neous block achieved in that study (ie, mean blockw4% at
2120 mV and 6% at 2100 mV) were much smaller than
those found in rabbit atrial myocytes in the present study.22
Though atrial-ventricular differences in the effects of ranola-
zine on the late Na1 current have previously been reported in
rabbit cardiac myocytes, to the best of our knowledge this
represents the ﬁrst report of atrial-ventricular differences in
the effects of ranolazine on the fast component of INa in rabbit
cells.28
Mechanism of ranolazine block
The data are consistent with preferential interaction of rano-
lazine with activated states of both atrial and ventricular Na1
channels, as has been suggested previously.22,29 Although
we did not investigate the possibility of ranolazine
interaction with the inactivated state of the channel (eg, by
varying the duration of the test pulses in the trains),
consideration of the physicochemical properties of the drug
and the structure of voltage-gated Na1 channels indicates
that preferential binding to the inactivated state is unlikely:
Ranolazine is thought to interact with the local anesthetic
binding site of voltage-gated Na1 channels.17,21 As
ranolazine has pKa values of 2.8 and 7.2, approximately
50% of the drug will be charged at physiological pH.30 Ac-
cess of the drug to the binding site is therefore most likely
through the cytosolic mouth to the pore and would require
channel activation. However, the degree of instantaneous
block by ranolazine evident at negative HPs at which there
was very little INa activation in the present study is striking,
particularly in atrial myocytes (Figure 1). Although fenestra-
tions identiﬁed in the x-ray crystallographic structure of Na1
channels have been suggested to represent hydrophobic path-
ways for access of neutral drugs to the local anesthetic bind-
ing site, the relatively large size of ranolazine (molecular
weightw427.5 g.mol21,w22 A length) argues against sig-
niﬁcant access of the drug via that route.29,31,32 On the other
hand, overlap in the voltage dependence of steady-state acti-
vation and inactivation will result in a small, but nevertheless
signiﬁcant, window current at negative voltages in both atrial
and ventricular myocytes (Figure 8). Thus, the instantaneous
block likely results from the small proportion of channels
activated at negative HPs. Notably, the voltage dependence
Figure 7 Effect of ranolazine (RAN) on INa recovery from inactivation. A: Recovery of INa from inactivation in atrial (ﬁlled symbols, n 5 6) and ventricular
(open symbols, n5 5) myocytes. Dashed lines represent ﬁts to Supplemental Equation 4. The holding potential during recovery was2120mV.B: Fitted fast (left-
hand panel) and slow (right-hand panel) time constants in control and in the presence of 30 mM RAN for atrial (ﬁlled columns) and ventricular (open columns)
myocytes. *P, .05; ***P, .001; 2-way repeated measures analysis of variance (RMANOVA) with Bonferroni post hoc test vs control.C:Mean amplitude of
slow component in control and in the presence of 30 mMRAN for atrial (ﬁlled columns) and ventricular (open columns) myocytes. *P, .05; 2-way RMANOVA
with Bonferroni post hoc test vs control.
Caves et al Atrial-Selective Na+ Current Block by Ranolazine 1663of instantaneous block in atrial myocytes corresponded with
the current density–voltage relation of the window current.
Thus, the difference between atrial and ventricular cells in
the voltage dependence of instantaneous block likely reﬂects
differences in the voltage dependence of activation of the
window current in the 2 cell types. Similarly, the greater de-
gree of instantaneous block in rabbit atrial myocytes in the
present study as compared with canine atrial myocytes pre-
sumably reﬂects the more negative position of the window
current on the voltage axis relative to the previously pub-
lished data.11,22,29 The mechanism underlying the more
negative voltage dependence of INa activation and
inactivation in the present study compared with previous
reports is unclear but, in principle, could reﬂect differences
in recording conditions (eg, temperature, composition of
solutions) and/or species differences in the biophysical
properties of cardiac Na1 channel isoforms.10–13,22,29
The accentuation of use-dependent block by ranolazine at
shorter DIs in atrial and ventricular myocytes in the presentFigure 8 The window current in atrial and ventricular myocytes. Data
plotted against the left-hand axis are window current densities calculated
from the parameters presented in Supplemental Table 1 for atrial (solid black
line) and ventricular (dashed black line) myocytes. Data plotted against the
right-hand axis show steady-state voltage-dependent activation and inactiva-
tion curves (I/Imax) according to the ﬁtted parameters presented in
Supplemental Table 1 for atrial (solid gray lines) and ventricular (dashed
gray lines) myocytes.study reﬂected incomplete recovery from block during the
DI when the channels tend to return toward the resting state.
The increase in use-dependent block with depolarized HP in
ventricular myocytes arises from slower recovery from acti-
vated/inactivated states to the resting state and slower disso-
ciation of the drug at the more positive potentials as the drug
is trapped in the inactivated channel. On the other hand, it
was striking that the use-dependent block in atrial myocytes
was reduced at depolarized HPs. This was presumably a
consequence of the voltage dependence of instantaneous
block in these cells: use-dependent block was reduced at de-
polarized potentials because the drug had gained access to the
local anesthetic binding site via activation of the window cur-
rent in these cells. Thus, the atrial-selective actions of ranola-
zine in the present study are largely consequent upon the
more negative voltage dependence of activation and inactiva-
tion of INa in atrial cells as compared with ventricular myo-
cytes.Conclusion
Differences exist between atrial and ventricular myocytes in
the biophysical properties of INa in rabbit cardiac myocytes.
The more negative voltage dependence of INa activation
and inactivation, together with trapping of the drug in the in-
activated channel, underlies atrial-selective INa inhibition by
ranolazine.Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrthm.2
017.06.012.References
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